LiBBY, short for Life's End Benefits of cannaBidiol and tetrahYdrocannabinol, was a Phase 2 trial of THC/CBD oil for agitation in hospice-eligible dementia patients. It reduced agitation quickly, but serious adverse events were twice as common with treatment as with placebo. For spouses and partners, the trial does not make retail THC or CBD safe or proven for home use.
Agitation here means restlessness, aggression, or distress in late dementia. Partners often face urgent decisions about calming strategies. This briefing explains what changed, what stayed risky, and what to discuss with care teams.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test, and in whom?
- How much did agitation improve?
- What should partners understand about safety?
- Why not try a retail product at home?
What did LiBBY test, and in whom?
The Alzheimer's Association states LiBBY enrolled 120 hospice-eligible patients with dementia-related agitation in a multicenter randomized double-blind placebo-controlled trial see the Alzheimer's Association trial release. Treatment was 2 mg THC with 100 mg CBD oil twice daily for 12 weeks. Only end-of-life patients qualified.
Support came from the NIH National Institute on Aging through the Alzheimer's Clinical Trial Consortium. The lead centers were the Medical University of South Carolina, Georgetown, and USC, working across 10 to 13 U.S. sites. These were small-sample topline Phase 2 conference results, not FDA approval, so they do not show dispensary products work for early dementia or spouses at home.
How much did agitation improve?
Neuroscience News reports a 6.27-point greater reduction than placebo on the Cohen-Mansfield Agitation Inventory at week 2. The gap widened to an 8.23-point greater reduction at week 12. The effect appeared early and held through the treatment period.
Clinician-rated global improvement was 83.9% on treatment versus 30.5% on placebo at week 2. By week 12, improvement was 87.2% versus 23.6%. For a partner managing late-stage restlessness, that difference means calmer days were more common with treatment in this closely monitored hospice setting.
What should partners understand about safety?
Neuroscience News reports overall adverse events were similar at 46.7% on THC/CBD versus 42.4% on placebo, but serious adverse events were 23.3% versus 11.9% read the Neuroscience News trial summary. Investigators judged none of the serious events drug-related. The patients were frail and near the end of life.
Similar overall events do not mean equal risk. A higher serious-event rate matters because falls, infections, hospital transfers, and confusion carry heavier costs in hospice care. Partners should weigh the agitation benefit against that vulnerability and ask what monitoring the trial provided that home care cannot match.
Why not try a retail product at home?
The FDA warns CBD can cause liver injury, drowsiness, diarrhea, mood changes, and drug interactions that raise side effects or lower benefit read the FDA consumer update. Only Epidiolex is approved for seizures, and no cannabis product is approved for dementia. Retail oils vary in dose, purity, and THC content.
Do not substitute a dispensary or online product for the trial oil. Talk with the hospice team or physician before any change to agitation care. Bring that one-week note, with exact product labels if CBD or THC is already in use, to the next hospice visit.
- Track triggers, sleep, pain, falls, and new medicines for one week
- List all sedatives, seizure drugs, liver drugs, and supplements
- Ask about proven calming steps, medication review, and what to do in a crisis
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: A Source-Checked Research Briefing for Spouses and Partners
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: A Source-Checked Research Briefing for Spouses and Partners
- Dementia With Multiple Etiologies in the 2026 NIA Report: Why the Findings May Not Change Care Yet for Spouses and Partners





